MARCH | APRIL | MAY | JUNE | 5pm CEST | 4pm BST | 11am EST | 8am PST
Real-World Evidence & Trials Masterclass Series 2021
Join our masterclass series to learn about perspectives on real-world evidence studies from a trialist / statistician and epidemiologist / clinician, explained in clear non-technical terms and illustrated with examples from drugs and devices in multiple therapy areas.
OXON Epidemiology will be hosting a Real-World Evidence Masterclass Series for all professionals interested in learning about the role of Real-World Data studies and their pros and cons compared with trials.
Real-World Evidence (RWE) is a key opportunity to better understand the diseases and patient needs. Besides, all RWE projects, except pragmatic trials, share the same scientific methodology as observational research. Thus, during these 4 monthly one-hour sessions, starting in March 2021, the attendees will learn about perspectives on RWE studies with the help of two experts in this particular field: Professor Stuart Pocock, renewed trialist and statistician, and Nawab Qizilbash, epidemiologist and clinician.
They will lead this Masterclass series, presenting the different topics in clear non-technical terms and illustrating them with examples from drugs and devices in multiple therapy areas.
Thus, if you are in Epidemiology, HEOR, Safety, Statistics, Medical Affairs, Market Access, Marketing, Project Management or Outsourcing in a biopharmaceutical or device company, don’t miss out on your chance to learn from leading experts.
See below our live sessions for you to register for any or all masterclasses.
Session 1: Non-randomized Comparative Effectiveness Studies: ‘The magic of randomization and the reality of Real-World Evidence studies’
On Wednesday, 17 March 2021 at 5-6 pm CET
Session 2: The Tyranny of Propensity Scores: The good and the bad
On Wednesday, 21 April 2021 at 5-6 pm CEST
Session 3: Non-randomized Comparative Safety Studies
On Wednesday, 19 May 2021 at 5-6 pm CEST
Session 4: Individualizing Benefit-Risk
On Wednesday, 16 June 2021 at 5-6 pm CEST
Who should attend
This Masterclass series is intended for a wide audience including: Epidemiology, HEOR, Safety, Statistics, Medical Affairs, Market Access, Marketing, Project Management and Outsourcing professionals in biopharmaceutical and device companies*.
You will learn about the role and pros and cons of Real-World Data studies compared with trials.
Guidance to overcome challenges in future Real-World Data studies will be discussed with Q&A sessions for technical and non-technical questions.
Professor of Medical Statistics, London School of Hygiene & Tropical Medicine
Author of >600 papers, including 100+NEJM/ Lancets, mainly of clinical trials and epidemiology; extensive experience of EMA/FDA and Data Monitoring Committee (including the Covid-19 adaptive platform DISCOVERY trial)
Senior Clinical Epidemiologist, OXON Epidemiology
Honorary Associate Professor in Pharmacoepidemiology, London School of Hygiene & Tropical Medicine and Clinical Observer, Internal Medicine, Madrid Hospitals.
Formerly: Director, Clinical Epidemiology, GSK and Honorary Consultant Physician, Radcliffe Hospitals, Oxford